25 February 2016 
EMA/CHMP/100611/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Giotrif 
afatinib 
On 25 February 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Giotrif. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim 
International GmbH.  
The CHMP adopted a new indication as follows: 
Giotrif as monotherapy is indicated for the treatment of locally advanced or metastatic NSCLC of 
squamous histology progressing on or after platinum-based chemotherapy. 
For information, the full indications for Giotrif will be as follows: 
“Giotrif as monotherapy is indicated for the treatment of  
−  Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); 
− 
locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-
based chemotherapy (see section 5.1).” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
